Combined use of artificial adjuvant vector cells and immunostimulant
The combination of artificial adjuvant vector cells with immunostimulants like immune checkpoint inhibitors enhances iNKT cells and CTLs, addressing the limitations of existing immunotherapies by improving immune activation against cancer and infections.
Patent Information
- Application Number
- JP2024125691
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-18
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-08-07
AI Technical Summary
Existing immunotherapies for cancer and infectious diseases are limited in their ability to effectively activate natural immunity and induce antigen-specific cytotoxic T cells and invariant natural killer T cells.
A pharmaceutical composition combining artificial adjuvant vector cells (aAVC) that express CD1d and are pulsed with CD1d ligand, along with immunostimulants such as immune checkpoint inhibitors or activators, to enhance innate and adaptive immune responses by increasing invariant natural killer T cells (iNKT cells) and antigen-specific cytotoxic T cells (CTLs).
The combination significantly enhances the number and function of iNKT cells and CTLs, thereby improving immune activation and therapeutic efficacy against cancer and infectious diseases.
Smart Images

Figure 2024156832000001 
Figure 2024156832000002 
Figure 2024156832000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for use in activating natural immunity, comprising an immunostimulant (immune checkpoint inhibitor or immune activator) that activates immunity by acting on an immune checkpoint. The present invention also relates to a combination of an artificial adjuvant vector cell and an immunostimulant (immune checkpoint inhibitor or immune activator). [Background technology]
[0002] Cells obtained by pulsing cells that co-express CD1d and a target protein with a CD1d ligand are called artificial adjuvant vector cells (aAVC), and induce natural immunity and adaptive immunity against the target protein in the subject to which they are administered (Patent Documents 1 to 3 and Non-Patent Document 1).
[0003] Among immunostimulants (immune checkpoint inhibitors or immune activators), immune checkpoint inhibitors weaken or release the suppressive effect on T cells by inhibiting the action of immune checkpoint molecules, thereby improving immune function and providing therapeutic effects against cancer and infectious diseases. Immunostimulants are preparations that activate immunity. More specifically, immune checkpoint inhibitors can promote the killing of cancer cells and cells infected by pathogens by antigen-specific cytotoxic T cells by weakening or releasing the suppression that antigen-specific cytotoxic T cells receive due to the action of immune checkpoint molecules (Patent Document 4). Immunostimulants can enhance the function of antigen-specific cytotoxic T cells. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO2007 / 097370 [Patent Document 2] WO2010 / 061930 [Patent Document 3] WO2013 / 018778 [Patent Document 4] WO2004 / 004771 [Non-patent literature]
[0005] [Non-Patent Document 1] Shimizu K. et al., 2007, J. Immunol., Vol. 178, pp2853-2861 Summary of the Invention
[0006] The present invention provides a composition for use in activating natural immunity, comprising an immunostimulant (immune checkpoint inhibitor or immune activator). The present invention also provides a combination of an artificial adjuvant vector cell and an immune checkpoint inhibitor.
[0007] The present inventors have found that an immunostimulant (immune checkpoint inhibitor or immune activator) increases invariant natural killer T cells (iNKT cells) involved in natural immunity, and increases antigen-specific cytotoxic T cells (CTLs, or CD8-positive T cells). The present inventors have found that the combined use of an immune checkpoint inhibitor and an artificial adjuvant vector cell (aAVC) increases iNKT cells, and increases antigen-specific cytotoxic T cells (CTLs, or CD8-positive T cells) against the antigen expressed in the aAVC. The present invention is based on these findings.
[0008] According to the present invention, the following industrially applicable inventions are provided. (1) A pharmaceutical composition comprising an artificial adjuvant vector cell, which is used in combination with an immunostimulant (an immune checkpoint inhibitor or an immune activator), A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen. (2) The pharmaceutical composition according to (1) above, wherein the artificial adjuvant vector cell has at least one of an exogenous nucleic acid encoding CD1d and an exogenous nucleic acid encoding a tumor antigen. (3) The pharmaceutical composition according to (1) or (2) above, wherein the CD1d ligand is α-galactosylceramide. (4) The pharmaceutical composition according to any one of (1) to (3) above, wherein the immunostimulant is at least one antibody selected from an anti-PD-1 antibody, an anti-Lag3 antibody, an anti-TIM-3 antibody, an anti-CTLA4 antibody (all of which are immune checkpoint inhibitors), and an anti-OX40 antibody, an anti-GITR antibody (all of which are immunostimulants). (5) A pharmaceutical composition comprising an immunostimulant according to any one of (1) to (3) above. (6) The pharmaceutical composition according to any one of (1) to (3) above, wherein the immunostimulant is a cytokine that activates the immune system. (7) An immunostimulant that acts on immune-related molecules to stimulate immunity, and is used in combination with artificial adjuvant vector cells or a pharmaceutical composition containing the cells, A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen. (8) A combination preparation of an immunostimulant (immune checkpoint inhibitor or immune activator) that activates immunity by acting on an immune checkpoint and an artificial adjuvant vector cell, A combination preparation in which the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen. (9) A composition for use in activating natural immunity, comprising an immunostimulant (immune checkpoint inhibitor or immune activator) that acts on an immune checkpoint to activate immunity. [Brief description of the drawings]
[0009] [Figure 1] FIG. 1 shows a scheme for the combined use of artificial adjuvant vector cells (aAVC) and an immunostimulant (immune checkpoint inhibitor or immune activator) (antibody: Ab) in an embodiment. [Diagram 2] FIG. 2 shows flow cytometry of antigen-specific cytotoxic T cells (CD8 positive T cells or CLTs) in mice administered aAVC expressing ovalbumin (OVA) as an antigen in the scheme according to FIG. 1 in combination with the indicated immune checkpoint inhibitors. [Diagram 3] FIG. 3 is a graph showing the number and ratio of antigen-specific CTLs obtained in FIG. [Figure 4] FIG. 4 shows flow cytometry of invariant natural killer T cells (iNKT cells) in mice administered aAVC expressing ovalbumin (OVA) as an antigen in the scheme according to FIG. 1 in combination with the indicated immune checkpoint inhibitors. [Diagram 5] FIG. 5 is a graph showing the number and percentage of iNKT cells obtained in FIG. [Figure 6] FIG. 6 shows a scheme for combined use of artificial adjuvant vector cells (aAVC) and an immunostimulant (IL-2) in an example. [Figure 7] FIG. 7 shows the percentage of antigen-specific T cells in the spleens of mice on day 14 in the scheme shown in FIG. [Figure 8] FIG. 8 is a graph of the results of FIG. [Figure 9] FIG. 9 shows a scheme of combined use of artificial adjuvant vector cells (aAVC) and immunostimulants (describe cytokines) in the examples. [Figure 10] FIG. 10 shows the percentage of antigen-specific T cells in the spleens of mice on day 14 in the scheme shown in FIG. [Figure 11] FIG. 11 is a graph of the results of FIG. 10 (number of antigen-specific T cells in the spleen). [Figure 12] FIG. 12 is a graph showing the results of FIG. 10 (proportion (%) of antigen-specific T cells in the spleen). [Figure 13] FIG. 13 shows the percentage of iNKT cells in the spleens of mice on day 14 in the scheme shown in FIG. [Figure 14] FIG. 14 shows the number of iNKT cells in the spleens of mice on day 14 in the scheme shown in FIG. Specific content of the invention
[0010] As used herein, a "subject" can be a mammal, including, for example, humans and non-human mammals.
[0011] As used herein, the term "treatment" includes therapeutic treatment and preventive treatment. As used herein, the term "treatment" includes delaying or stopping the progression of a disease or condition, as well as improving and curing a disease or condition. As used herein, the term "prevention" includes inhibiting the onset of a disease or condition and reducing the incidence of the disease or condition.
[0012] As used herein, "artificial adjuvant vector cells" (aAVC) refer to cells expressing CD1d and antigens (e.g., molecules expressed on targets such as cancer antigens, viral antigens, and microbial antigens), and pulsed with CD1d. CD1d-pulsed cells can be obtained by culturing cells expressing CD1d with a CD1d ligand. After culturing, CD1d ligands not attached to the cells can be removed by washing. CD1d is a protein of the CD1 family and is an MHC class I-like glycoprotein. CD1d can present glycolipids to activate, for example, iNKT cells. Examples of CD1d include human CD1d, such as a protein having an amino acid sequence registered under GenBank accession number AAH27926.1. CD1d ligand refers to a glycolipid that binds to CD1d. Examples of CD1d ligands include α-GalCer (α-galactosylceramide), α-C-GalCer (α-C-galactosylceramide), iGB3 (isoglobotrihexosylceramide), GD3 (ganglioside 3), GSL-1 (α-linked glucuronic acid), and GSL-1'SA (galacturonic acid), which can be used as CD1d ligands. Examples of CD1d ligands that can be used preferably include α-GalCer and α-C-GalCer.
[0013] When aAVC is administered to a mammal, it activates iNKT cells, matures dendritic cells, and induces innate immunity as well as adaptive immunity. When aAVC expresses a protein, adaptive immunity against the protein is also induced. aAVC induces innate and adaptive immunity whether dendritic cells, cancer cells, or other cells (e.g., somatic cells) are used. aAVC induces innate and adaptive immunity in a subject whether the subject is allogeneic or allogeneic to which it is administered. When aAVC is allogeneic, after inducing innate and adaptive immunity in the subject, the aAVC itself can be eliminated as non-self by the subject's immune system. By expressing a target protein in aAVC, adaptive immunity specific to the target protein can be induced in a subject administered with aAVC. In aAVC, the target protein is a full-length protein or a partial peptide. aAVC expresses CD1d and is pulsed with a CD1d ligand. The aAVC may have an exogenous gene encoding CD1d operably linked to a regulatory sequence. The aAVC may have an exogenous gene encoding a target protein operably linked to a regulatory sequence. The aAVC may express an endogenous target protein.
[0014] As used herein, a "cell" is a mammalian cell, and may be, for example, a human cell. Cells include dendritic cells and non-dendritic cells. Cells include tumor cells and non-tumor cells. Cells include cancer cells and non-cancer cells. Cells include immortalized cells and primary cells. Cells include somatic and non-somatic cells. Cells may be syngeneic or allogeneic to the subject to which they are administered. Cells include, for example, human cells and human cell lines, such as human embryonic kidney cell lines, e.g., HEK293 cells.
[0015] In this specification, "natural immunity" refers to a mechanism that detects and eliminates invading foreign substances and abnormal cells through phagocytosis and pattern recognition. Natural immunity is mainly carried out by neutrophils, macrophages, natural killer cells (NK cells), natural killer T cells (NKT cells), and dendritic cells. In contrast, "adaptive immunity" is a mechanism that effectively eliminates re-invading foreign substances by memorizing their characteristics. Adaptive immunity is mainly carried out by lymphocytes such as T cells (cytotoxic T cells (CTL) and helper T cells) and B cells. Since adaptive immunity is established after natural immunity, it takes time to respond. In natural immunity, dendritic cells present in peripheral tissues phagocytose and ingest pathogens and break them down into peptides. After that, they migrate to lymph nodes and spleen and mature, and present antigen peptides to T cells that control adaptive immunity. Then, adaptive immunity is induced, and killer T cells and B cells against the antigen are activated, and attack against the foreign substance begins. In this way, natural immunity induces adaptive immunity through dendritic cells. Immature dendritic cells do not have the ability to present antigens, but have strong phagocytic activity, and as they mature, their phagocytic activity weakens and their antigen-presenting ability strengthens. They also highly express adhesion molecules and costimulatory molecules, and acquire strong T cell activation ability. aAVC is a vaccine system that can activate both natural and adaptive immunity by inducing the activation of invariant natural killer T cells (iNKT cells), which are natural immune lymphocytes, and promoting the maturation of dendritic cells. aAVC activates iNKT cells through CD1d bound to iNKT cell ligands (e.g., α-GarCer), but the aAVC itself is destroyed in the body and taken up by dendritic cells. aAVC also recruits killer T cells to tumor tissues and other tissues.
[0016] In this specification, "antibody" refers to an immunoglobulin, a protein having a structure in which two heavy chains (H chains) and two light chains (L chains) stabilized by a pair of disulfide bonds are associated with each other. The heavy chain is composed of a heavy chain variable region VH, heavy chain constant regions CH1, CH2, CH3, and a hinge region located between CH1 and CH2, and the light chain is composed of a light chain variable region VL and a light chain constant region CL. Among them, the variable region fragment (Fv) composed of VH and VL is a region that is directly involved in antigen binding and provides diversity to the antibody. The antigen-binding region composed of VL, CL, VH, and CH1 is called the Fab region, and the region composed of the hinge region, CH2, and CH3 is called the Fc region. Among the variable regions, the region that directly contacts the antigen changes greatly and is called the complementarity-determining region (CDR). The portion other than the CDR that has relatively few mutations is called the framework region (FR). The light chain and heavy chain variable regions each have three CDRs, which are called heavy chain CDR1-3 and light chain CDR1-3, respectively, from the N-terminus. In this specification, "anti-A antibody" means an antibody that binds to A. An anti-A antibody can specifically bind to A. In this specification, "specifically binds to A" means that the antibody has a stronger binding affinity to A than the binding affinity to other proteins other than A. The antibody may be a monoclonal antibody or a polyclonal antibody. The antibody may be of any isotype, such as IgG, IgM, IgA, IgD, or IgE. The antibody may be prepared by immunizing a non-human animal such as a mouse, rat, hamster, guinea pig, rabbit, or chicken, or may be a recombinant antibody, a chimeric antibody, a humanized antibody, or a fully humanized antibody. A chimeric antibody is an antibody in which fragments of antibodies derived from different species are linked together. The term "humanized antibody" refers to an antibody in which the corresponding positions in a human antibody have been replaced with an amino acid sequence characteristic of an antibody of non-human origin, and examples thereof include an antibody having heavy chain CDR1-3 and light chain CDR1-3 of an antibody produced by immunizing a mouse or rat, with all other regions, including the four framework regions (FR) of the heavy and light chains, derived from a human antibody. Such antibodies are sometimes called CDR-grafted antibodies. The term "humanized antibody" also includes human chimeric antibodies. A "human chimeric antibody" is an antibody in which the constant region of a non-human antibody is replaced with the constant region of a human antibody. In a human chimeric antibody, from the viewpoint of enhancing ADCC activity, for example, the subtype of the human antibody used in the constant region can be IgG1.
[0017] As used herein, the term "antigen-binding fragment" refers to an antibody fragment having binding affinity to an antigen. Specific examples of the antibody fragment include, but are not limited to, Fab consisting of VL, VH, CL and CH1 regions, F(ab')2 in which two Fabs are linked by a disulfide bond at the hinge region, Fv consisting of VL and VH, scFv which is a single-chain antibody in which VL and VH are linked by an artificial polypeptide linker, and bispecific antibodies such as diabody type, scDb type, tandem scFv type, and leucine zipper type.
[0018] As used herein, "immune checkpoint inhibitor" refers to a drug that activates immunity by releasing the suppression of immune cells caused by immune checkpoint molecules. As used herein, "immune activator" refers to a drug that activates immune cells (e.g., a drug that targets T cells, particularly a drug that stimulates CTLs, e.g., a drug that stimulates immune costimulatory molecules). An immune activator can be a drug that is selective for a target. As used herein, immune checkpoint inhibitors and immune activators are collectively referred to as "immune activators." Examples of immune checkpoint molecules include programmed cell death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin domain and mucin domain-3 (TIM-3), lymphocyte activation gene 3 (LAG-3), and V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA). The immune checkpoints that each of them is responsible for are called the PD-1 immune checkpoint, the CTLA-4 immune checkpoint, the TIM-3 immune checkpoint, the LAG-3 immune checkpoint, and the VISTA immune checkpoint. Immune checkpoint inhibitors can inhibit the function of immune checkpoints, for example, by binding to immune checkpoint molecules or their ligands. For example, the PD-1 immune checkpoint can be inhibited by inhibiting the binding between PD-1 and PD-L1 or PD-L2, the CTLA-4 immune checkpoint can be inhibited by inhibiting the binding between CTLA-4 and CD80 or CD86, and the TIM-3 immune checkpoint can be inhibited by inhibiting the binding between TIM-3 and galectin-9.Also, by inhibiting the binding between LAG-3 and MHC class II molecules, the LAG-3 immune checkpoint can be inhibited. Also, by inhibiting the binding between VISTA and VSIG-3 / IGSF11, the VISTA immune checkpoint can be inhibited. In this way, one or more immune checkpoints selected from the group consisting of the PD-1 immune checkpoint, the CTLA-4 immune checkpoint, the TIM-3 immune checkpoint, the Lag3 immune checkpoint, and the VISTA immune checkpoint can be inhibited. The antibody that inhibits the binding of the two proteins can bind to a receptor or a ligand. For example, the antibody that inhibits the PD-1 immune checkpoint can be an antibody selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody (e.g., nivolumab, pemprolizumab, avelumab, atezolizumab, and durvalumab). The antibody that inhibits the CTLA-4 immune checkpoint may be an antibody selected from the group consisting of anti-CDLA-4 antibody, anti-CD80 antibody, and anti-CD86 antibody (e.g., ipilimumab and tremelimumab). The antibody that inhibits the TIM-3 immune checkpoint may be an antibody selected from the group consisting of anti-TIM-3 antibody and anti-galectin-9 antibody (e.g., MGB453). The antibody that inhibits the VISTA immune checkpoint may be an antibody selected from the group consisting of anti-VISTA antibody and anti-VSIG-3 / IGSF11 antibody (e.g., JNJ-61610588). Also, examples of immune costimulatory molecules include OX40 and glucocorticoid-induced TNF-related protein (GITR). For immune costimulatory molecules such as GITR and OX40, when stimulated with their respective agonist antibodies (i.e., agonist antibodies that bind to GITR and agonist antibodies that bind to OX40) or their respective agonists, killer T cells are activated and regulatory T cells are suppressed in function. In this way, immune costimulatory molecules can be stimulated, for example, one or more immune costimulatory molecules selected from the group consisting of GITR and OX40 can be stimulated. The immunostimulatory agent for GITR immune costimulatory molecules (agonist antibodies or agonists of GITR immune costimulatory molecules) can be anti-GITR antibodies and GITR agonists (e.g., TRX518 and MEDI1873). Also, the immunomodulator against OX40 immune co-stimulatory molecule (agonist antibody or agonist of OX40 immune co-stimulatory molecule) can be anti-OX40 antibody and OX40 agonist (e.g., GSK3174998, MOXR0916, PF-04518600, and MEDI0562). In addition, as the anti-OX40 agonist antibody, any of the anti-OX40 agonist antibodies described in WO2012027328A, WO2013028231A, WO2015153514A, and WO2015095423A can be used.
[0019] The immune activator may be a medicine that activates immunity. The immune activating medicine may contain an immune activating cytokine, for example, a cytokine that activates T cells (for example, an interleukin that activates T cells). Examples of immune activating cytokines include cytokines such as IL-2. IL-2 is a cytokine classified into a group called Th1 cytokines, and is mainly produced from activated T cells. The human IL-2 protein may have, for example, an amino acid sequence registered under NBCI Reference No. NP_000577.2. And, the human IL-2 may be, for example, an IL-2 having a sequence corresponding to the amino acid sequence registered under NBCI Reference No. NP_000577.2. Of the amino acid sequence registered under NBCI Reference No. NP_000577.2, amino acids 1 to 20 are considered to be a signal sequence, and mature IL-2 has an amino acid sequence of amino acids 21 to 153. Therefore, when expressing IL-2 in cells, a nucleic acid encoding IL-2 containing a signal sequence is introduced into cells, and when administering as a protein, IL-2 without a signal sequence can be used.
[0020] Furthermore, examples of pharmaceutical agents that activate the immune system include factors selected from the group consisting of IL-2, IL-2 / anti-IL-2 antibody complex, IL-7, IL-15, IL-15 / anti-IL15Rα antibody complex, IL-12, IL-18, IL-21, IL-23, and IL-27, and may be used in combination with aAVC in the present invention.
[0021] The IL-2 / anti-IL-2 antibody complex is a complex of interleukin-2 (IL-2) and an anti-IL-2 antibody (i.e., an antibody that binds to IL-2). IL-2 is a factor that binds to the IL-2 receptor and induces IL-2-mediated T cell proliferation, etc. There are two types of anti-IL-2 antibodies: regulatory T cell (Treg)-inducing antibodies that suppress the immune system, and immune-activating antibodies that induce effector T cells. The former anti-IL-2 antibodies (JES6-1 in mice and 5344 in humans) are antibodies that easily bind to cells that strongly express the IL-2 receptor α chain (CD25 (IL-2Rα)), and the complex acts on Treg. The latter anti-IL-2 antibodies (e.g., S4B6 for mice, MAB602 for humans, or TCB2) are antibodies that easily bind to cells with high expression of the IL-2 receptor β chain (CD122 (IL-2Rβ)), and the complexes formed therewith have been reported to act on effector and memory T cells (e.g., CD4 T cells and CD8 T cells) and NK cells (PNAS 2010, 107:11906, PNAS 2010, 107:2171). In the present invention, an antibody that binds more strongly to cells with high expression of the IL-2 receptor β chain, for example, an antibody that binds more strongly to cells with high expression of the IL-2 receptor β chain and enhances IL-2 function (e.g., an antibody that acts on cells selected from effector or memory T cells and NK cells, or an antibody that induces the cells), can be used to form a complex with IL-2. It has also been reported that the half-life of soluble IL-2 in vivo is short, at several hours, but the half-life of the IL-2 / anti-IL-2 antibody complex is extended. Thus, the function of IL-2 is enhanced by using a complex of IL-2 and an antibody that binds to the IL-2 receptor β chain. In particular, IL-2 and an anti-IL-2 antibody can be administered in a form in which they have been previously complexed. In this way, IL-2 can be administered in a form in which it has been complexed with an anti-IL-2 antibody. IL-2 can be human IL-2, and the antibody can be an anti-human IL-2 antibody, and can be a human chimeric antibody, a humanized antibody, or a human antibody. Examples of human IL-2 include IL-2 having an amino acid sequence registered under GenBank registration number: AAB46883.1, or human IL-2 having an amino acid sequence corresponding thereto.As used herein, the phrase "having an amino acid sequence corresponding to amino acid sequence X" is used to include a homologue of the protein having amino acid sequence X (e.g., a naturally occurring homologue) that retains the function of the protein.
[0022] Interleukin-7 (IL-7) is a cytokine that plays an important role in the development of T cells and the maintenance of naive and memory CD8 positive T cells. IL-7 can be human IL-7. Examples of human IL-7 include IL-7 having an amino acid sequence registered under GenBank accession number: AAH47698.1 or human IL-7 having an amino acid sequence corresponding thereto.
[0023] Interleukin-15 (IL-15) is a cytokine that is involved in T cell activation and proliferation, similar to IL-2. IL-15 can be human IL-15. Human IL-15 can be, for example, IL-15 having the amino acid sequence registered under GenBank accession number: CAA71044.1 or human IL-15 having the amino acid sequence corresponding thereto.
[0024] The IL-15 / IL-15Rα complex will be described. As mentioned above, IL-15 is a cytokine that activates T cells. IL-15Ra is a receptor to which IL-15 binds. It is known that when IL-15 is presented to effector and memory T cells (e.g., CD4 T cells and CD8 T cells) and NK cells in a state bound to IL-15Ra, these cells are stimulated more strongly (this phenomenon is called "trans-presentation") (Dubois S et al. Immunity 2002, 17:537). It is also said that the half-life of IL-15 is extended by forming a complex between IL-15 and IL-15Ra (Guo Y et al. Cytokine Growth Factor Rev 2017, 38:10). Therefore, IL-15 can be administered to a subject as a complex with IL-15Ra. In this way, IL-15 can be administered to a subject in the form of a complex with IL-15Ra. IL-15Ra may be human IL-15Ra, for example, IL-15Ra having the amino acid sequence registered under GenBank Accession No. CAG33345.1 or human IL-15Ra having an amino acid sequence corresponding thereto.
[0025] Interleukin-12 (IL-12) is a heterodimer of IL-12A and IL-12B. IL-12 is said to be involved in the activation and differentiation induction of T cells and NK cells. IL-12 can be human IL-12 (i.e., a heterodimer of human IL-12 subunit α and human IL-12 subunit β). Human IL-12A can be a 35 kDa protein, and examples of such protein include IL-12A having the amino acid sequence registered under GenBank Accession No. AAI04985.1 or human IL-12A having the corresponding amino acid sequence. Examples of human IL-12B include IL-12B having the amino acid sequence registered under GenBank Accession No. EAW61576.1 or human IL-12B having the corresponding amino acid sequence. IL-12 can be provided by complexing IL-12A with IL-12B.
[0026] Interleukin-18 (IL-18) is a cytokine that induces interferon gamma. It is said to have functional commonality with IL-12. IL-18 exists intracellularly as a 24 kDa precursor, but when cleaved by active caspase-1, it is released outside the cell as a mature 18 kDa cytokine. In the present invention, this mature IL-18 can be used as IL-18. IL-18 can be human IL-18, and examples of human IL-18 include human IL-18 having the amino acid sequence registered under UniProtKB / Swiss-Prot registration number: Q14116.1 or human IL-18 having an amino acid sequence corresponding thereto.
[0027] Interleukin-21 (IL-21) is a type I cytokine that has homology with IL-2 and IL-15. IL-21 is mainly produced by activated T cells. IL-21 includes human IL-21. Human IL-21 includes, for example, IL-21 having the amino acid sequence registered under GenBank accession number: EAX05226.1 or human IL-21 having the amino acid sequence corresponding thereto.
[0028] Interleukin-23 (IL-23) is a cytokine composed of IL-23 subunit α and p40 subunit of IL-12. IL-23 is said to promote the production and survival of a T cell subset called TH17 cells. IL-23 may be human IL-23. Human IL-23A may be, for example, IL-23 subunit α having the amino acid sequence of 20th to 189th amino acids of the amino acid sequence of human IL-23 subunit α precursor (amino acid numbers 1 to 189) registered in NCBI reference sequence: NP_057668.1 or an amino acid sequence corresponding thereto. IL-23 subunit α and p40 subunit of IL-12 may be provided as a complex.
[0029] Interleukin-27 (IL-27) is a heterodimer of interleukin-30 (IL-30) and the Epstein-Barr virus-induced gene 3 (EBI3) subunit of interleukin-27. IL-27 is said to be involved in the proliferation of antigen-specific naive CD4 positive T cells and the promotion of their differentiation into a Th1 phenotype. IL-30 can be human IL-30, and the human IL-30 can be, for example, human IL-30 having an amino acid sequence registered under UniProtKB / Swiss-Prot registration number: Q8NEV9.2 (amino acid numbers 1 to 28 are considered to be a signal sequence) or human IL-30 having an amino acid sequence corresponding thereto. Furthermore, the EBI3 subunit of IL-27 may be the EBI3 subunit of human IL-27, and the EBI3 subunit of human IL-27 may be the EBI3 subunit of human IL-27 having the amino acid sequence registered under UniProtKB / Swiss-Prot registration number: Q8K3I6.1 (amino acid numbers 1 to 28 are believed to be a signal sequence) or the EBI3 subunit of human IL-27 having an amino acid sequence corresponding thereto.
[0030] In one embodiment, the cytokines selected from the group consisting of IL-2, IL-7, IL-15, IL-12, IL-18, IL-21, IL-23, and IL-27 may all have their signal peptides cleaved off.
[0031] The inventors have found that the combination of an immune stimulant (immune checkpoint inhibitor or immune activator) and aAVC increases the number and ratio of antigen-specific CTLs against antigens expressed by aAVC. The inventors have also found that the combination of an immune checkpoint inhibitor and aAVC increases the number and ratio of iNKT cells. The action of immune checkpoint inhibitors is thought to be to elicit the original action of CTLs by inhibiting the immune checkpoint of antigen-specific CTLs. According to the inventors, immune checkpoint inhibitors increased lymphocytes of the innate immune system and increased antigen-specific CTLs.
[0032] According to the present invention, an immunostimulant (immune checkpoint inhibitor or immune activator) can activate natural immunity and induce antigen-specific CTLs. Thus, according to the present invention, there is provided a composition comprising an immunostimulant (immune checkpoint inhibitor or immune activator) for use in activating natural immunity and / or for use in inducing antigen-specific CTLs. Here, inducing antigen-specific CTLs means increasing the number and proportion of antigen-specific CTLs.
[0033] According to the present invention, an immunostimulant (immune checkpoint inhibitor or immune activator) can enhance the ability of aAVC to induce antigen-specific CLT and iNKT cells. Therefore, according to the present invention, (a) a pharmaceutical composition comprising an artificial adjuvant vector cell in combination with an immune checkpoint inhibitor, A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express a tumor antigen; (b) an immune checkpoint inhibitor used in combination with an artificial adjuvant vector cell or a pharmaceutical composition comprising the cell, A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express a tumor antigen; (c) A combination preparation of an immunostimulant (immune checkpoint inhibitor or immune activator) and an artificial adjuvant vector cell, A combination preparation, in which the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express a tumor antigen {wherein the combination preparation may be a pharmaceutical composition comprising an immunostimulant (immune checkpoint inhibitor or immunoactivator) and the artificial adjuvant vector cells}; and (d) A pharmaceutical composition for use in activating natural immunity, comprising an immune checkpoint inhibitor, or a pharmaceutical composition for use in increasing antigen-specific CTL, comprising an immune checkpoint inhibitor. (The above (a) to (d) may be collectively referred to as the medicament of the present invention).
[0034] In the pharmaceutical compositions (a) and (b) and the combination preparation described in (c), the artificial adjuvant vector cells can express endogenous CD1d. The artificial adjuvant vector cells may also express exogenous CD1d. Exogenous CD1d can be expressed in the artificial adjuvant vector cells by introducing a nucleic acid encoding the exogenous CD1d. When the nucleic acid is DNA, the DNA is operably linked to a promoter. The nucleic acid may be mRNA. When endogenous CD1d is highly expressed, it is not necessary to introduce exogenous CD1d into the artificial adjuvant vector cells. The artificial adjuvant vector cells may express an antigen, such as a tumor antigen or an antigen of an invading foreign substance.
[0035] Tumor antigens are antigens that are expressed more in tumors than in normal cells. Tumor antigens can be antigens that are expressed in tumors at a surface molecule count that is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold, and 1,000-fold or more higher than that of normal cells. Tumor antigens include solid tumors, including epithelial and non-epithelial tumors, and tumor antigens in hematopoietic tissues. Tumor antigens include, but are not limited to, oncoantigens and neoantigens such as MART-1, ZMelan-A, Mage-1, Mage-3, gpl00, tyrosinase, CEA, PSA, CA-125 erb-2, Muc-1, Muc-2, TAG-72, AES, FBP, C lectin, NY-ESO-1, galectin-4 / NY-CO-27, Pec60, HER-2 / erbB-2 / neu, telomerase, G250, Hspl05, point-mutated ras oncogene, point-mutated p53 oncogene, and carcinoembryonic antigen (see, for example, JP 2005-139118 A, JP 2004-147649 A, JP 2002-112780 A, and JP 2004-222726 A). Antigens of tumors (e.g., leukemia) in hematopoietic tissues include, but are not limited to, proteinase3, WT-1, hTERT, PRAME, PML / RAR-a, DEK / CAN, cyclophilin, TEL-MAL1, BCR-ABL, OFA-iLRP, Survivin, idiotype, sperm protein 17, SPAN-Xb, CT27, and MUC1.
[0036] Antigens of invading foreign substances include pathogen antigens. Pathogen antigens can be pathogenic virus antigens, pathogenic microbial antigens, or pathogenic protozoan antigens. Examples of pathogenic viral antigens include, but are not limited to, GP-120, pl7, GP-160 (all of which are HIV), NP, HA (all of which are influenza virus), HBs Ag, HBV envelope protein, core protein, polymerase protein, NS3, NS5 (all of which are hepatitis virus), HSVdD (herpes simplex virus), EBNA1, 2, 3A, 3B and 3C, LMP1 and 2, BZLF1, BMLF1, BMRF1, BHRF1 (all of which are EB virus), Tax (HTLV-I), SARS-CoV spike protein (SARS virus), CMV pp50, CMV pp65, IE-1 (all of which are CMV), and E6 and E7 proteins (all of which are HPV) (see, for example, JP 2004-222726 A). Examples of pathogenic microbial antigens include antigens expressed in pathogenic bacteria (e.g., Chlamydia, Mycobacteria, Legionella) and pathogenic yeast (e.g., Aspergillus, Candida). Examples of pathogenic protozoan antigens include antigens expressed in malaria and schistosomiasis.
[0037] The artificial adjuvant vector cell may be an isolated cell or a purified cell. The artificial adjuvant vector cell may be a cell line. The artificial adjuvant vector cell may be a human or a non-human animal (e.g., a non-human mammal and a non-human primate) cell. The non-human animal includes monkeys, chimpanzees, gorillas, orangutans, bonobos, dogs, cats, cows, pigs, sheep, horses, mice, rats, guinea pigs, hamsters, and rabbits. The artificial adjuvant vector cell may be an autologous cell, an allogeneic cell, or a xenogeneic cell with respect to the subject to be administered. This is because it is ultimately phagocytosed by dendritic cells.
[0038] The artificial adjuvant vector cell may be a somatic cell. Somatic cells include stomach, small intestine (e.g., duodenum, jejunum, ileum, colon), large intestine, rectum, lung, spleen, kidney, liver, thymus, spleen, thyroid, adrenal gland, prostate, ovary, uterus, bone marrow, skin, and peripheral blood. The cell of the present invention may also be a specific cell type in the above tissue or a cell type present in a tissue other than the above tissue. Such cell types include, for example, epithelial cells, endothelial cells, epidermal cells, stromal cells, fibroblasts, adipocytes, mammary cells, mesangial cells, spleen cells, nerve cells, glial cells, immune cells (e.g., T cells, B cells, NK cells, NKT cells, macrophages, mast cells, neutrophils, basophils, eosinophils, monocytes), and precursor cells and stem cells of these cells.
[0039] The antigen expressed in the artificial adjuvant vector cell may be an antigen derived from the cell, or an antigen introduced exogenously. When the antigen expressed in the artificial adjuvant vector cell is an antigen derived from the cell, the artificial adjuvant vector cell can be prepared from, for example, a tumor cell or a pathogen-infected cell. Examples of the pathogen-infected cell include a virus-infected cell, a microorganism-infected cell, and a protozoan-infected cell.
[0040] The artificial adjuvant vector cell may be a non-transformed or transformed cell. Transformation refers to artificial gene introduction. For example, a cell into which DNA or mRNA is exogenously introduced is called a transformed cell. When the artificial adjuvant vector cell endogenously expresses CD1d and an antigen, the artificial adjuvant vector cell can be created without transformation.
[0041] Artificial adjuvant vector cells can be made from antigen-presenting cells (APCs) or non-APCs. APCs include, for example, dendritic cells, macrophages, B cells, Langerhans cells, and activated T cells.
[0042] The artificial adjuvant vector cells can be prepared by pulsing with CD1d ligand. Pulsing of cells with CD1d ligand can be performed by culturing cells expressing CD1d in a medium in the presence of CD1d ligand. In this way, the cells expressing the target antigen and expressing CD1d can be made to present the CD1d ligand. When the cells expressing the target antigen and expressing CD1d present the CD1d ligand, immune activation against the target antigen can occur in vivo.
[0043] As the medium, a medium that can be used for cell culture can be appropriately used. Examples of the medium include MEM medium, DMEM medium, αMEM medium, Ham's medium, RPMI1640 medium, Fischer's medium, and mixed media thereof. The medium can contain additional components selected from the group consisting of serum (e.g., FCS), serum replacement (e.g., knockout serum replacement (KSR)), fatty acids or lipids, amino acids, vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, and inorganic salts.
[0044] The nucleic acid encoding the exogenous CD1d and the nucleic acid encoding the exogenous antigen can be introduced into a cell using a gene expression vector. The nucleic acid encoding the exogenous CD1d and the nucleic acid encoding the exogenous antigen may be included in one gene expression vector or in separate gene expression vectors. When the nucleic acid encoding the exogenous CD1d and the nucleic acid encoding the exogenous antigen are included in one gene expression vector, they may be included in the mRNA in a polycistronic manner so as to be transcribed as one mRNA, or may be included in the mRNA in a monocistronic manner so as to be transcribed as separate mRNAs. When the two genes are included in the mRNA in a polycistronic manner, an internal ribosome entry site (IRES) can be interposed between each gene. The nucleic acid encoding the exogenous CD1d and the nucleic acid encoding the exogenous antigen can be operably linked to a promoter suitable for transcription into mRNA in a cell. The promoter means a minimal sequence sufficient to induce transcription in a cell. Promoters include viral promoters, mammalian promoters, and yeast promoters (e.g., mammalian CMV promoter, yeast alcohol oxidase, phosphoglycerokinase promoter, lactose inducible promoter, galactosidase promoter, adeno-associated virus promoter, baculovirus promoter, poxvirus promoter, retrovirus promoter, adenovirus promoter, SV40 promoter HMG (hydroxymethylglutaryl coenzyme A) promoter, TK (thymidine kinase) promoter, 7.5K or H5R poxvirus promoter, adenovirus type 2 MPC late promoter, alpha antrypsin promoter, factor IX promoter, immunoglobulin promoter, CFTR surfactant promoter, albumin promoter, and transferrin promoter). Nucleic acid encoding foreign CD1d and nucleic acid encoding foreign antigen may be mRNA, for example, the above-mentioned mRNA.The mRNA contains elements necessary for the translation of the encoded protein, and when introduced into a cell, it induces the translation of the encoded protein. Gene introduction into a cell can be carried out by a conventional method.
[0045] In the present invention, among the immunostimulants, the immune checkpoint inhibitors include PD-1 immune checkpoint inhibitors, CTLA-4 immune checkpoint inhibitors, TIM-3 immune checkpoint inhibitors, Lag3 immune checkpoint inhibitors, and VISTA immune checkpoint inhibitors.In addition, among the immunostimulants, the immune activators include the immune activators for GITR and the immune activators for OX40 (for example, one or more antibodies selected from the GITR antibody and the OX40 antibody as the respective agonists and the respective agonist antibodies).In the present invention, the immune activator for OX40 may more preferably be the OX40 antibody, which is the immune activator for OX40.
[0046] In the present invention, aAVC and an immunostimulant (immune checkpoint inhibitor or immune activator) may be administered simultaneously or separately. In the present invention, aAVC may be administered once or multiple times. In the present invention, an immunostimulant (immune checkpoint inhibitor or immune activator) may be administered once or multiple times. In one embodiment of the present invention, aAVC may be administered once, and an immunostimulant (immune checkpoint inhibitor or immune activator) may be administered multiple times.
[0047] In the present invention, the aAVC and the immunostimulant (immune checkpoint inhibitor or immune activator) may be provided in one package or in separate packages. When provided in one package, the aAVC and the immune checkpoint inhibitor may be mixed in the same pharmaceutical composition or may be separately contained in separate pharmaceutical compositions. In one embodiment of the present invention, the aAVC and the immune checkpoint inhibitor are provided separately in separate packages. In one embodiment of the present invention, the aAVC and the immune checkpoint inhibitor are separately contained in separate pharmaceutical compositions in one package. In one embodiment of the present invention, the aAVC and / or the immunostimulant (immune checkpoint inhibitor or immune activator) may further include a package insert containing instructions for combining the aAVC and the immunostimulant (immune checkpoint inhibitor or immune activator).
[0048] In some embodiments of the present invention, the aAVC may be provided in a frozen state. In some embodiments of the present invention, the immunostimulant (immune checkpoint inhibitor or immune activator) may be provided as an infusion or injection. In some embodiments of the present invention, the aAVC may be provided in a frozen state and gamma sterilized.
[0049] The present invention also provides a pharmaceutical composition for use in activating natural immunity (particularly iNKT cells), comprising an immunostimulant (immune checkpoint inhibitor or immune activator). Activation of natural immunity (particularly iNKT cells) can increase antigen-specific CTLs. Therefore, the present invention also provides a pharmaceutical composition for use in increasing antigen-specific CTLs, comprising an immunostimulant (immune checkpoint inhibitor or immune activator). According to the present invention, the increase in antigen-specific CTLs can occur through activation of natural immunity. According to the present invention, in this aspect, the immune checkpoint inhibitor includes one or more immune checkpoint inhibitors (e.g., antibodies) selected from the group consisting of PD-1 immune checkpoint inhibitors, CTLA-4 immune checkpoint inhibitors, TIM-3 immune checkpoint inhibitors, Lag3 immune checkpoint inhibitors, and VISTA immune checkpoint inhibitors. In this embodiment, the present invention also includes an activator of one or more immune co-stimulatory molecules selected from the group consisting of GITR and OX40 (e.g., OX40L, an agonist or an agonist antibody), and in particular an activator of OX40 (e.g., OX40L, an agonist or an agonist antibody of OX40). In one embodiment of the present invention, the pharmaceutical composition for use in activating natural immunity (particularly iNKT cells) may be a pharmaceutical composition for use in expanding iNKT cells. In one embodiment of the present invention, the pharmaceutical composition for use in activating natural immunity (particularly iNKT cells) or the pharmaceutical composition for use in expanding iNKT cells may comprise an immunostimulatory agent (e.g., an anti-OX40 antibody, which is an agonist antibody) selected from the group consisting of an anti-PD-1 antibody, an anti-Lag3 antibody, an anti-VISTA antibody, an anti-OX40 antibody, and an anti-CTLA4 antibody. In one embodiment of the present invention, a pharmaceutical composition for use in increasing antigen-specific CTLs may comprise an immunostimulant selected from the group consisting of an anti-PD-1 antibody, an anti-TIM-3 antibody, an anti-CTLA4 antibody, and an anti-OX40 antibody (e.g., an anti-OX40 antibody, which is an agonistic antibody). For example, the agonist antibody of OX40 can be selected by screening hybridomas that produce antibodies that bind to OX40 based on the affinity of the antibodies produced by the hybridomas to OX40, and then using OX40-expressing cells (e.g., HEK293 cells) that express reporter (e.g., luciferase) genes under the control of NF-κB response elements, the OX40 antibody obtained can be selected based on the improvement of luciferase activity. Such a test system can be purchased, for example, from BPS Bioscience (Catalog # 60482).
[0050] The immunostimulant (immune checkpoint inhibitor or immune activator) of the present invention may further include an excipient. The aAVC of the present invention may further include an excipient. The excipient may include any suitable excipient. The immune checkpoint inhibitor of the present invention may be administered by parenteral administration such as intravenous administration, intratumoral administration, subcutaneous administration, and intraperitoneal administration, and may be formulated in a dosage form suitable for these administration routes. The aAVC of the present invention may be administered by parenteral administration such as intravenous administration, intratumoral administration, subcutaneous administration, and intraperitoneal administration, and may be formulated in a dosage form suitable for these administration routes.
[0051] The medicament of the present invention can be used to treat cancer and / or infectious diseases. Examples of cancer include solid tumors (e.g., epithelial tumors, non-epithelial tumors) and tumors in hematopoietic tissues. More specifically, examples of solid tumors that can be treated by the medicament of the present invention include digestive cancers (e.g., gastric cancer, colon cancer, colorectal cancer, rectal cancer), lung cancer (e.g., small cell carcinoma, non-small cell carcinoma), spleen cancer, kidney cancer, liver cancer, thymus cancer, spleen cancer, thyroid cancer, adrenal cancer, prostate cancer, bladder cancer, ovarian cancer, uterine cancer (e.g., endometrial cancer, cervical cancer), bone cancer, skin cancer, sarcoma (e.g., Kaposi's sarcoma), melanoma, blastoma (e.g., neuroblastoma), adenocarcinoma, squamous cell carcinoma, non-squamous cell carcinoma, brain tumor, and cancers caused by recurrence and metastasis of these solid tumors. Tumors in hematopoietic tissues that can be treated by the medicament of the present invention include leukemia (e.g., acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), adult T-cell leukemia-lymphoma (ATL), myelodysplastic syndrome (MDS)), lymphoma (e.g., T lymphoma, B lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma), myeloma (multiple myeloma), and cancer due to recurrence and metastasis of these tumors. Infectious diseases that can be treated by the medicament of the present invention include, for example, infections caused by the above-mentioned pathogens.
[0052] According to the present invention, a method of treating cancer or an infectious disease in a subject in need thereof is provided, comprising administering to the subject an immunostimulant (immune checkpoint inhibitor or immune activator) and administering aAVC. The aAVC can express an antigen specific to the cancer or infectious disease (foreign substance causing the infectious disease) to be treated. According to the present invention, the pharmaceutical of the present invention can be administered. In one embodiment, the pharmaceutical of the present invention can be administered until an increase in the number of cytotoxic T cells is confirmed. In one embodiment, the present invention can further comprise measuring the number of cytotoxic T cells after administering the pharmaceutical of the present invention. In one embodiment, the present invention can comprise detecting an increase in the number of cytotoxic T cells in the subject after administering the pharmaceutical of the present invention. The cytotoxic T cells can have antigen specificity for the antigen expressed by the aAVC. In one embodiment, the therapeutically effective amount is an amount that shows therapeutic effectiveness against cancer or an infectious disease, but can be an amount that increases cytotoxic T cells in the subject.
[0053] According to the present invention, there is provided the use of an immunostimulant (immune checkpoint inhibitor or immune activator) and / or an aAVC in the manufacture of a medicament of the present invention. According to the present invention, there is provided an immune checkpoint inhibitor and / or an aAVC for use in the treatment method of the present invention. EXAMPLES
[0054] Example 1: Combination of artificial adjuvant vector (aAVC) and immune checkpoint inhibitor In this example, the effect of combining aAVC with an immunostimulant (immune checkpoint inhibitor or immune activator) was examined.
[0055] Mice (C57BL / 6 mice, 6 weeks old, n=2) were administered a combination of aAVC and immune checkpoint inhibitors. The administration scheme was as shown in Figure 1. Specifically, aAVC expressing ovalbumin (OVA) was administered on day 0, and an immune checkpoint inhibitor (antibody) was administered at 200 μg / dose on days 0, 3, and 5, respectively, and the number and percentage of antigen-specific CD8 positive T cells and the number and percentage of iNKT cells were examined on day 7.
[0056] aAVC-OVA was obtained by expressing a gene encoding CD1d and a gene encoding OVA as an antigen in NIH3T3 cells, and then adding 0.5 mg / mL of α-galactosylceramide (α-GalCer) to the medium. 5 The dose was determined by cell / animal dose.
[0057] The immune checkpoint inhibitors used as immunomodulators were anti-PD-1 antibody (BioXcell, product number: BE0146), anti-Lag3 antibody (BioXcell, product number: BE0174), anti-TIM-3 antibody (BioXcell, product number: B8.2C12), anti-VISTA antibody (BioXcell, product number: BE0310), and anti-CTLA4 antibody (BioXcell, product number: BE0164). The immune stimulants used were anti-OX40 antibody (BioXcell, product number: BE0031) or anti-GITR antibody (BioXcell, product number: BE0063). All were administered at a dose of 200 μg / animal / administration.
[0058] aAVC-OVA was administered intravenously and immunomodulators were administered intraperitoneally.
[0059] Seven days after aAVC-OVA administration, the spleens of the mice were collected and antigen-specific CD8 positive T cells (cytotoxic T cells) and invariant natural killer T cells (iNKT cells) were analyzed. For CD8 positive T cells, splenocytes were isolated from the spleen, stained with CD3, CD8, CD44 antibodies and OVA-tetramer, and analyzed using FACS (manufacturer BD, product name Cancto II). Splenocytes were gated on CD3 and CD8 positive cells for CD8 T cells, and developed with CD44 and OVA-tetramer. CD44 positive and OVA-tet positive cells were regarded as OVA-specific CD8 positive T cells, and the number and percentage of cells were measured. The percentage is the percentage (%) of OVA-specific CD8 positive T cells among CD8 T cells.
[0060] The results were as shown in FIG. 2. As shown in FIG. 2, in the immunostimulant combination group, the proportion of OVA-specific CD8 positive T cells was increased compared to the aAVC-OVA alone administration group. Specifically, the proportion of OVA-specific CD8 positive T cells increased in the anti-PD-1 antibody combination group, the anti-TIM-3 antibody combination group, the anti-CTLA4 antibody combination group, and the anti-OX40 antibody combination group, and the increase in the proportion of OVA-specific CD8 positive T cells was particularly remarkable in the anti-OX40 antibody combination group. The number and proportion of OVA-specific CD8 positive T cells were graphed and shown in FIG. 3. As shown in FIG. 3, the number and proportion of OVA-specific CD8 positive T cells increased in the anti-PD-1 antibody combination group, the anti-TIM-3 antibody combination group, the anti-CTLA4 antibody combination group, and the anti-OX40 antibody combination group, and the increase in the number and proportion of OVA-specific CD8 positive T cells was particularly remarkable in the anti-OX40 antibody combination group.
[0061] In addition, the number and percentage of iNKT cells in splenocytes were analyzed. Specifically, spleens were isolated 14 days after cell administration and incubated with CD1d-tetramer / Gal-APC, a CD1d tetramer preloaded with α-GalCer labeled with aphycocyanin (APC), and PerCP / Cy5. (R) CD3-PerCP / Cy5, CD3 labeled with (R) Staining with CD3+ And CD1d-tetramer / Gal + The cells were counted as iNKT cells. Next, the frequency of iNKT cells in the spleen was calculated. Furthermore, the total number of cells in the spleen of each immunized mouse was multiplied by the frequency to calculate the number of iNKT cells. As a result, as shown in FIG. 5, the number and proportion of iNKT cells were increased in the anti-PD-1 antibody combination group, the anti-Lag3 antibody combination group, the anti-VISTA antibody combination group, the anti-OX40 antibody combination group, and the anti-CTLA4 antibody combination group, and in particular, the number and proportion of iNKT cells were increased in the anti-OX40 antibody combination group.
[0062] iNKT cells induce the activation of natural killer T cells (NK cells) and dendritic cells, which are responsible for innate immunity, as well as the activation of B cells and T cells, which are responsible for adaptive immune responses. By combining with immune checkpoint inhibitors, aAVC was shown to enhance the ability to elicit innate and adaptive immunity. Immune checkpoint inhibitors enhance T cell-mediated immunity by removing the suppression of T cells (cytotoxic T cells; CTLs) that are responsible for adaptive immunity, while the immune activator used in this study enhances T cell-mediated immunity by directly stimulating immune function. The results of this study show that the combined use of an immune activator with aAVC enhances the activation of natural immunity, and it cannot be considered that the additive effect of the induction of natural immunity by aAVC and the enhancement of adaptive immunity by the immune checkpoint inhibitor was achieved. The results of this study demonstrated that immunostimulants enhance the ability of aAVC to elicit natural immunity and not only relieve the suppression of cytotoxic T cells but also increase the number of cytotoxic T cells, making them a potential method for achieving more effective cancer immunotherapy. Of course, immune checkpoint inhibitors are expected to enhance the ability of aAVC to activate innate immunity and induce antigen-specific immunity, and immunostimulants are expected to enhance the therapeutic effects of aAVC on cancer and infectious diseases.
[0063] Example 2: Combination of aAVC and immune activators Next, the effect of combining an immune activator with aAVC was confirmed by the scheme of combining aAVC with cytokines shown in Figure 6. Mice were administered aAVC-OVA in the same manner as in Figure 1. 5 × 10 3 U / dose of IL-2 was administered for 7 days. Spleens were harvested from mice on day 14. CD8 T cells were gated from spleen cells using CD3 and CD8 positive cells, and developed with CD44 and OVA-tetramer. CD44 positive and OVA-tet positive cells were regarded as OVA-specific CD8 positive T cells, and their number and percentage of cells were measured. The percentage is the percentage (%) of OVA-specific CD8 positive T cells among CD8 T cells. aAVC-OVA was prepared as in Example 1. aAVC-OVA was administered at 5×10 5 The dose was determined by cell / animal dose.
[0064] The results are shown in FIG. 7 (flow cytometry results) and FIG. 8 (number (left) and percentage (right) of antigen-specific CD8-positive T cells). As shown in FIGS. 7 and 8, in the group administered aAVC-OVA in combination with IL-2, the number and percentage of antigen-specific CD8-positive T cells were significantly increased compared to the group administered aAVC-OVA alone. This demonstrated that immune activators are useful in combination with aAVC.
[0065] Furthermore, the effect of combining aAVC with an immune activator (IL-2 / anti-IL-2 antibody complex, IL-7, or IL-15) was confirmed by the scheme of combining aAVC with cytokines shown in FIG. 9. aAVC-OVA was administered to mice as in FIG. 1. Cytokines were administered daily for 7 days at the doses listed per mouse starting from the 7th day after administration. The spleens of the mice were collected on the 14th day. CD8 T cells were gated from the spleen cells by CD3 and CD8 positive cells, and developed with CD44 and OVA-tetramer. The number and percentage of CD44 positive and OVA-tet positive cells were determined as OVA-specific CD8 positive T cells. The percentage is the percentage (%) of OVA-specific CD8 positive T cells among CD8 T cells. aAVC-OVA was prepared as in Example 1. aAVC-OVA was administered at 5×10 5 The dose was determined by cell / animal dose.
[0066] The results are shown in Figure 10 (flow cytometry results), Figure 11 (number of antigen-specific CD8 positive T cells in the spleen), and Figure 12 (proportion of antigen-specific CD8 positive T cells). As shown in Figures 10 to 12, the number and proportion of antigen-specific CD8 positive T cells increased when any cytokine was used in combination, compared to administration of aAVC alone, but the increase was remarkable when either the IL-2 / anti-IL-2 antibody complex or IL-15 was administered.
[0067] Furthermore, the number and ratio of iNKT cells in splenocytes were analyzed as described in Example 1. The results are shown in Figure 13 (flow cytometry results) and Figure 14 (number of iNKT cells in the spleen). As shown in Figures 13 and 14, the number of iNKT cells in the spleen increased when any cytokine was used in combination, compared to administration of aAVC alone. Thus, the administered immune activator was able to enhance the natural immunity-inducing ability of aAVC.
Claims
1. A pharmaceutical composition comprising an artificial adjuvant vector cell in combination with an immunostimulant, A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen.
2. The pharmaceutical composition according to claim 1 , wherein the artificial adjuvant vector cell has at least one of an exogenous nucleic acid encoding CD1d and an exogenous nucleic acid encoding a tumor antigen.
3. The pharmaceutical composition according to claim 1 or 2, wherein the CD1d ligand is α-galactosylceramide.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the immunostimulant is at least one antibody selected from an anti-PD-1 antibody, an anti-Lag3 antibody, an anti-TIM-3 antibody, an anti-CTLA4 antibody, and an anti-OX40 antibody.
5. The pharmaceutical composition according to any one of claims 1 to 3, wherein the immunostimulant is an anti-OX40 antibody.
6. The pharmaceutical composition according to any one of claims 1 to 3, wherein the immunostimulant is a cytokine that activates the immune system.
7. An immune checkpoint inhibitor used in combination with an artificial adjuvant vector cell or a pharmaceutical composition comprising said cell, A pharmaceutical composition, wherein the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen.
8. A combination preparation of an immunostimulant that activates immunity by acting on an immune checkpoint and an artificial adjuvant vector cell, A combination preparation in which the artificial adjuvant vector cells express CD1d, are pulsed with a CD1d ligand, and express an antigen.
9. A composition for use in activating natural immunity, comprising an immunostimulant that acts on an immune checkpoint to activate immunity.
Citation Information
Patent Citations
Anticancer drug containing Anti-PD-1 antibody or Anti-PD-l1 antibody
JP2010083863A
nkt cell subsets for in vivo persistence and therapeutic activity and their proliferation
JP2018516548A
IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
WO2007097370A1
IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
WO2010061930A1
Anti-ox40 antibodies and methods of using the same
WO2012027328A2
